TNFSF13B and systemic lupus erythematosus: A clinical trial study on 13 SLE patients treated with various dosages of belimumab demonstrated a selective depletion of naïve and transitional B cell subpopulations; in contrast, memory B cells and plasma cells were less susceptible to selective BLyS inhibition (Jacobi et al., 2010).